The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

ADHD is one of the most common neurodevelopmental disorders in childhood and is associated with impaired functioning and negative outcomes for development. Individuals diagnosed with ADHD are often ...

Medications for attention-deficit/hyperactivity disorder (ADHD) have some side effects that are common, while others are more ...

The differing time–action profiles provided by these long-acting MPH formulations may allow clinicians to target specific periods of the day that are particularly relevant for a patient ...

The objective of this review was to bring together the evidence available from head-to-head studies of long-acting MPH formulations and to increase understanding of their basic properties, discuss ...

Stanford University researchers have discovered why some people with attention deficit hyperactivity disorder may do well on their medicine for a while but struggle down the road.

Methylphenidate, a central nervous system stimulant that can significantly reduce symptoms in about 70% of users with the condition and that the World Health Organisation (WHO) recommends for the ...

10mg, 20mg ext-rel tabs 5 Adults and Children: May use ER tabs in place of IR tabs when the 8hr dose of methylphenidate ER corresponds to the titrated 8hr dose of methylphenidate IR. Max 60mg/day ...